Figure 4
NS8593 attenuates kidney atrophy in the UUO mouse model. (a) Pictures of representative CLK and UUO kidneys isolated from UUO mice at day 7 after ureteral obstruction surgery. The non-treatment control group was injected with vehicle daily (n = 5, upper panels). NS8593 (5 mg/kg) was injected intraperitoneally daily from post-surgery day 0 to day 6 (n = 4, lower panel). Scale bars depict 5 mm. (b) Representative pictures of Masson’s trichrome staining taken from one CLK and two representative UUO kidney sections (magnification x200, see Methods). Collagen fibers, an indicator of degree of fibrosis, appear in green. The cytoplasm appears in light red. UUO kidneys in the NS8593 treatment group (lower right panels) have substantially reduced manifestation of green compared to control (upper right panels). Scale bars, 100 μm. (c) The intensities in (b) were graded semi-quantitatively17,28 as follows: G0 (grade 0, 0%, white bars); G1 (grade 1, ≤20% in interstitial area colored green, grey bars); G2 (grade 2, 21–50%, red dot bars); G3 (grade 3, 51–80%, blue line bars) and G4 (grade 4, ≥81%, black line bars). Average grading of each mouse was used for statistical analysis. *p < 0.005; CLK vs. UUO kidney with NS8593 treatment, **p < 0.001; CLK vs. UUO kidney with non-treatment, #p < 0.005 comparing UUO kidneys in non-treatment vs. NS8593 treatment groups.
